Abstract
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease response in chronic-phase CML. Omacetaxine mepesuccinate, a first in class cetaxine, has been evaluated by clinical trials in TKI-insensitive/resistant CML. Omacetaxine inhibits synthesis of anti-apoptotic proteins of the Bcl-2 family, including (myeloid cell leukaemia) Mcl-1, leading to cell death. Omacetaxine effectively induced apoptosis in primary CML stem cells (CD34+38lo) by downregulation of Mcl-1 protein. In contrast to our previous findings with TKIs, omacetaxine did not accumulate undivided cells in vitro. Furthermore, the functionality of surviving stem cells following omacetaxine exposure was significantly reduced in a dose-dependant manner, as determined by colony forming cell and the more stringent long-term culture initiating cell colony assays. This stem cell-directed activity was not limited to CML stem cells as both normal and non-CML CD34+ cells were sensitive to inhibition. Thus, although omacetaxine is not leukaemia stem cell specific, its ability to induce apoptosis of leukaemic stem cells distinguishes it from TKIs and creates the potential for a curative strategy for persistent disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM . Homoharringtonine: history, current research, and future direction. Cancer 2001; 92: 1591–1605.
de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007; 110: 2779–2780.
Quintas-Cardama A, Cortes J . Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 2008; 9: 1029–1037.
Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S . Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009; 23: 1446–1454.
Quintas-Cardama A, Kantarjian H, Cortes J . Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009; 115: 5382–5393.
Powell RG, Weisleder D, Smith Jr CR . Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 1972; 61: 1227–1230.
Gurel G, Blaha G, Moore PB, Steitz TA . U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 2009; 389: 146–156.
Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006; 5: 723–731.
Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303–3311.
Akgul C . Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009; 66: 1326–1336.
Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093–2098.
Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y et al. A common signaling cascade may underlie ‘addiction’ to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006; 10: 425–435.
Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532–4539.
Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.
Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843–2853.
Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016–4019.
Konig H, Holyoake TL, Bhatia R . Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329–2338.
Kobayashi T, Ruan S, Clodi K, Kliche KO, Shiku H, Andreeff M et al. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 1998; 16: 1587–1591.
Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 2007; 21: 2204–2206.
Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109: 248–255.
Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T et al. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009; 63: 859–864.
Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV . Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16: 2349–2357.
Chen R, Gandhi V, Plunkett W . A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66: 10959–10966.
Tipping AJ, Deininger MW, Goldman JM, Melo JV . Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 31: 1073–1080.
Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907–14912.
Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. Targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010; 17: 427–442.
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109–1123.
Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010; 115: 2241–2250.
Acknowledgements
HGJ was supported by William Thyne Centenary Fellowship, Dr Rhona Reid Charitable Trust, and Louis and Marion Ferrar Trust. We are grateful to Kara Melchizedek for her contribution to cell-line data through her summer vacation project sponsored by the McGuigan family and the Pathological Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that E Allan, Dr Jørgensen and Prof Holyoake received research support from ChemGenex Pharmaceuticals; Dr A Craig, an employee of ChemGenex Pharmaceuticals, originated and participated in the concept discussion that led to the experimental work.
Additional information
Supplementary Information accompanies the paper on the Leukaemia website
Rights and permissions
About this article
Cite this article
Allan, E., Holyoake, T., Craig, A. et al. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 25, 985–994 (2011). https://doi.org/10.1038/leu.2011.55
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.55
Keywords
This article is cited by
-
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
BMC Cancer (2024)
-
Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia
Frontiers of Medicine (2019)
-
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Molecular Cancer (2018)
-
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
BMC Cancer (2018)
-
A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected
Oncology and Therapy (2018)